Researcher.Life Logo

Multiple Sclerosis Journal : Impact Factor & More

eISSN: 1477-0970pISSN: 1352-4585

Key Metrics

CiteScore
9.6
H-Index
147
Impact Factor
5 - 10
SJR
Q1Neurology
SNIP
1.52
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Multiple Sclerosis Journal

Multiple Sclerosis Journal Journal Specifications

Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1995
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Multiple Sclerosis Journal ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Multiple Sclerosis Journal

ACTRIMS Forum 2026.
  • 1 May 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS: YES.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS? Commentary.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS? No.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
ACTRIMS Forum 2026.
  • 1 May 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS: YES.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS? Commentary.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS? No.
  • 26 Apr 2026
  • Multiple sclerosis (Houndmills, Basingstoke, England)

FAQs on Multiple Sclerosis Journal